Amolyt Pharma
France-based company specialized in developing therapeutic peptides for rare endocrine and related diseases
Amolyt Pharma has raised €129M across 1 funding round from 16 investors, most recently a Series C round in Jan 2023. Based in Lyon, France; active in Healthtech. Data as of 28 Oct 2026.
Lyon, Franceamolytpharma.com ↗
Total raised
€129M
€129,020,194
Funding rounds
1
Investors
16
distinct backers
Active since
2023-01
latest 2023-01
Funding by year
EUR raised per yearAmolyt Pharma — funding by year — interactive chart.
Data table
| Amolyt Pharma — funding by year | |
|---|---|
| 2023 | €129M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-09 | Series C | €129M | Andera Partners,ATEM,Crédit Agricole Création,CTI Life Sciences,EQT Life Sciences,Innobio 2+10 more | View deal → |
Investors
16Related news
- French pharma Amolyt nets €130 million series C co-led by Sofinnova Partnerstech.eu · 2023-01
- Amolyt Pharma Raises $138M in Series C Financingfinsmes.com · 2023-01
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData